IGF-IR与前列腺癌的研究进展

前列腺癌是男性每年肿瘤相关死亡的第二大致死因。数十年来，雄激素剥夺疗法是治疗晚期或转移性前列腺癌患者的黄金标准，但这种治疗策略仅获得最初的效益，最终进展为去势抵抗性前列腺癌，所有的治疗，仅仅相对延长生存期。胰岛素样生长因子1型受体(IGF-1R)的过度表达介导前列腺癌细胞的生存。阻断IGF-1R及其下游信号通路，具有抑制前列腺癌细胞增殖、分化及促凋亡的效应。本文就IGF-1R表达与前列腺癌的发生、进展及迁移的关系，以及靶向治疗IGF-1R信号通路的研究进展予以综述。

Progress in the study of insulin-like growth factor receptor-1 and prostate cancer

Prostate cancer is the second leading cause of cancer related deaths in men each year. For decades, androgen deprivation therapy is and has been the gold standard for treatment of patients with advanced or metastatic prostate cancer, but this treatment strategy only shows benefit initially and the tumors recur as castration-resistant pros-tate cancer eventually, with only relatively prolonged survival. Overexpression of the insulin-like growth factor-1 recep-tor (IGF-1R) has been shown to mediate the survival of prostate cancer cells. Blocking IGF-1R and its downstream sig-naling pathway can inhibit the proliferation, differentiation and apoptosis of prostate cancer cells. Here is to make a re-view of the relationship between IGF-1R expression and the occurrence, progression and migration of prostate cancer, with research progress of targeting IGF-1R signaling pathway.